Theravance - Margin operasi TBPH

TBPH (theravance.com) - tandha merek perusahaan

Risks for Theravance Biopharma (TBPH) are linked to royalty volatility and the outcomes of ampreloxetine trials. Strategic alliances with industry behemoths help effectively promote respiratory treatments. The operating profit margin history clearly demonstrates these processes, where the value of 2.10 serves as the current metric. The company's growth potential is based on scalability: the launch of mass production for patented drugs following research promises high returns.

TBPH - Rentabilitas operasi theravance.com ing rentang 04.07.2022 - 10.10.2026

Rincian analitis perusahaan Theravance Biopharma (TBPH)

- rega lan prakiraan konsensus rega:
Analisis komprehensif perusahaan:theravance.com, TBPH
Barang utama Theravance Corp

Investors assess an asset's operational strength through the efficiency of cost management. For Theravance Biopharma (TBPH), royalties and patent protection serve as key factors here, reducing the budgetary burden. Tracking the operating margin allows for the determination of the revenue share remaining after all production and administrative expenses are paid. This percentage reflects the business's actual ability to generate profit before tax deductions. High values confirm the company's resilience to regulatory barriers.

Pesaing Theravance Biopharma

Rentabilitas operasi haleon.com|Rentabilitas operasi KVUE|Rentabilitas operasi Verona Pharma (VRNA)|Jyong Biotech (MENS) - Tingkat bathi adhedhasar bathi operasi|Margin operasi LGND (Ligand Pharma)|Amneal Pharmaceuticals Inc - Rentabilitas operasi|PRGO - Rentabilitas operasi|Alvotech Corp (ALVO) - Margin dodolan operasi|LQDA: Margin operasi|Rentabilitas dodolan operasi glpg.com (GLPG)|Rentabilitas operasi ANI Pharmaceuticals Inc|MNKD: Tingkat bathi operasi|Margin dodolan operasi AMPH (Amphastar)|PCRX - Rentabilitas dodolan operasi|Margin operasi SPRY (ars-pharma.com)|Rasio bathi operasi AQST (Aquestive Therapeutics)|SCPH: Margin dodolan operasi|Rentabilitas dodolan operasi Tectonic Therapeutic|TNXP: Margin operasi|SXT China (SXTC) - Margin operasi|Rentabilitas operasi eupraxiapharma.com|BioHarvest Sciences (BHST) - Rentabilitas kegiatan operasi|Rentabilitas operasi Invizyne (EXOZ)|ORMP - Rentabilitas dodolan operasi|Margin operasi ENTX (Entera Bio)|Tingkat bathi adhedhasar bathi operasi MindWalk Therapeutics|ABVC: Margin dodolan operasi|CPIX - Margin operasi|QNTM (Quantum BioPharma) - Margin dodolan operasi|Margin bathi operasi FGEN (FibroGen)|TELO (Telomir Pharmaceuticals Corp) - Margin operasi|Margin operasi ranitherapeutics.com|Rentabilitas operasi Synergy CHC Corp. (SNYR)|Rallybio Corp - Rentabilitas dodolan miturut bathi operasi|lexariabioscience.com - Margin dodolan operasi|Margin operasi Pulmatrix Inc PULM|Pheton Holdings - Margin operasi|Margin bathi operasi APM|Lyra Therapeutics, Inc. (LYRA) - Rentabilitas operasi|Rentabilitas dodolan operasi Impact BioMedical, Inc. (IBO)|Rentabilitas operasi TNF Pharma|YCBD: Tingkat bathi operasi|Margin operasi PRFX|CYTO - Rentabilitas dodolan operasi|Rentabilitas operasi Lipella LIPO|Rasio bathi operasi OPTN (OptiNose, Inc.)|PIRS - Rentabilitas operasi|Procaps (PROC) - Margin dodolan operasi|PTPI: Margin operasi|Qilian International (QLI) - Margin operasi|Rentabilitas operasi Acelyrin, Inc.|Margin operasi TFF Pharmaceuticals, Inc.